RCS - Angle PLC - Supporting characterisation of CTCs in HNSCC

AngleAnnouncement

25/10/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231025:nRSY1680Ra&default-theme=true

RNS Number : 1680R  Angle PLC  25 October 2023

 For immediate release  25 October 2023

 

ANGLE plc ("the Company")

 

RESEARCH DEMONSTRATES POTENTIAL OF THE PARSORTIX SYSTEM TO SUPPORT POWERFUL
CHARACTERISATION OF CTCS IN HEAD AND NECK CANCER

 

41 key biomarkers including the immune checkpoint proteins PD-L1, CTLA4 and
CD39 successfully evaluated

 

Providing key information which could support the development of personalised
treatment strategies in HNSCC

 

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with
innovative circulating tumour cell (CTC) diagnostic solutions for use in
research, drug development and clinical oncology, is pleased to announce the
publication of a study using the Parsortix system that sheds new light on the
phenotypic characteristics of CTCs in Head and Neck Squamous Cell Carcinoma
(HNSCC).

 

The study, conducted by researchers at the University of Birmingham, UK,
demonstrates the feasibility of using mass cytometry, a powerful technique
widely used for single cell analysis, for the comprehensive characterisation
of CTCs captured by the Parsortix system in HNSCC patients. This advanced
technology enables simultaneous analysis of multiple proteins on and within
individual CTCs, providing a deep understanding of their phenotypic status and
diversity. As a marker-independent method for CTC harvesting, the Parsortix
system was able to isolate a diversity of CTCs revealing a correlation between
epithelial to mesenchymal transition and immune checkpoint protein expression.
 

 

HNSCC is an aggressive, genetically complex, and difficult to treat group of
cancers with limited options for early detection and monitoring.  Head and
Neck cancers are a significant global health concern with ~900,000 new cases
each year at an estimated cost to the global economy of more than US$40
billion per annum. The findings of this study provide new insight into the
molecular heterogeneity of HNSCC and offers the potential to enable
development of more precise and personalised treatment strategies for patients
and real-time monitoring of treatment response. Furthermore, the protocol
established in this publication holds promise as a tool for the use of
proteomic data, obtained from Parsortix harvested CTCs, to be used for novel
biomarker development and the potential for identification of patients who may
be eligible for immune checkpoint inhibitor therapy.

 

The study is published as a peer-reviewed journal article in the British
Journal of Cancer and is available online at
https://angleplc.com/publications/ (https://angleplc.com/publications/) .

 

Principal Investigator, Dr Karl Payne, NIHR Clinical Lecturer in Oral &
Maxillofacial Surgery from the Institute of Cancer and Genomic Sciences,
University of Birmingham, UK, commented:

"To our knowledge, our work represents the first use of cell suspension mass
cytometry to characterise CTCs. With this protocol, phenotype and activation
status of critical intracellular cell signalling proteins can be measured in
CTCs and peripheral blood immune cells. By allowing high-dimensional
single-cell CTC data to be obtained from patients recruited across multiple
research sites, we believe our method will accelerate clinical study
recruitment and enable robust analysis of CTCs in rare cancers."

 

ANGLE Chief Scientific Officer, Karen Miller, commented:

"We are pleased to share this peer-reviewed publication by the University of
Birmingham demonstrating the high-throughput and high sensitivity of mass
cytometry for downstream multiplexed analysis of both surface and
intracellular proteins on and in CTCs. In this study, the heterogeneity of CTC
sub-groups and their relationship to targetable markers, in particular the
druggable immune checkpoints, is notable. The Parsortix system allows for the
unbiased isolation and harvest of CTCs and as such, can enable the evaluation
of phenotypically diverse CTCs in a patient's blood. This could lead to future
improvements in clinical decision making."

 

For further information:

 

 ANGLE plc
 Andrew Newland, Chief Executive         +44 (0) 1483 343434

 Ian Griffiths, Finance Director

 Berenberg (NOMAD and Joint Broker)      +44 (0) 20 3207 7800

 Toby Flaux, Ciaran Walsh, Milo Bonser

 Jefferies (Joint Broker)                +44 (0) 20 7029 8000

 Thomas Bective, Shaam Vora

 FTI Consulting

 Simon Conway, Ciara Martin              +44 (0) 203 727 1000

 Matthew Ventimiglia (US)                +1 (212) 850 5624

 

 

For Frequently Used Terms, please see the Company's website on
https://angleplc.com/investor-relations/glossary/
(https://angleplc.com/investor-relations/glossary/)

 

For Research Use Only. Not for use in diagnostic procedures.

 

 

Notes for editors

 

About ANGLE plc

 

ANGLE is a world-leading liquid biopsy company with innovative circulating
tumour cell (CTC) diagnostic solutions for use in research, drug development
and clinical oncology using a simple blood sample. ANGLE's FDA cleared and
patent protected circulating tumour cell (CTC) harvesting technology known as
the Parsortix(®) PC1 System enables complete downstream analysis of the
sample including whole cell imaging and proteomic analysis and full genomic
and transcriptomic molecular analysis.

 

ANGLE's commercial businesses are focusing on diagnostic products and clinical
services. Diagnostic products include the Parsortix(®) system and associated
consumables. The clinical services business is offered through ANGLE's
GCP-compliant laboratories in the UK and the United States.  Services include
custom made assay development and clinical trial testing for pharma.

 

Over 80 peer-reviewed publications have demonstrated the performance of the
Parsortix system. For more information, visit www.angleplc.com
(http://www.angleplc.com)

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFEFFWLEDSESS